Download MendeleyDiscovery of a 3-Pyridylacetic Acid Derivative (TAK-100) as a Potent, Selective and Orally Active Dipeptidyl Peptidase IV (DPP-4) Inhibitor.
Miyamoto, Y., Banno, Y., Yamashita, T., Fujimoto, T., Oi, S., Moritoh, Y., Asakawa, T., Kataoka, O., Yashiro, H., Takeuchi, K., Suzuki, N., Ikedo, K., Kosaka, T., Tsubotani, S., Tani, A., Sasaki, M., Funami, M., Amano, M., Yamamoto, Y., Aertgeerts, K., Yano, J., Maezaki, H.(2011) J Med Chem 53: 3517-3531
- PubMed: 21218817
- DOI: https://doi.org/10.1021/jm101236h
- Primary Citation of Related Structures:
3O95, 3O9V - PubMed Abstract:
Inhibition of dipeptidyl peptidase IV (DPP-4) is an exciting new approach for the treatment of diabetes. To date there has been no DPP-4 chemotype possessing a carboxy group that has progressed into clinical trials. Originating from the discovery of the structurally novel quinoline derivative 1, we designed novel pyridine derivatives containing a carboxy group. In our design, the carboxy group interacted with the targeted amino acid residues around the catalytic region and thereby increased the inhibitory activity. After further optimization, we identified a hydrate of [5-(aminomethyl)-6-(2,2-dimethylpropyl)-2-ethyl-4-(4-methylphenyl)pyridin-3-yl]acetic acid (30c) as a potent and selective DPP-4 inhibitor. The desired interactions with the critical active-site residues, such as a salt-bridge interaction with Arg125, were confirmed by X-ray cocrystal structure analysis. In addition, compound 30c showed a desired preclinical safety profile, and it was encoded as TAK-100.
Organizational Affiliation:
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Osaka 532-8686, Japan.
